OBIO PE Ratio & Valuation,Is OBIO Overvalued

OBIO Relative Valuation

OBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OBIO is overvalued; if below, it's undervalued.

Historical Valuation

Orchestra Biomed Holdings Inc (OBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.70. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：4.30

Fair

-2.72

-2.08

EV/EBITDA

Orchestra Biomed Holdings Inc. (OBIO) has a current EV/EBITDA of -2.08. The 5-year average EV/EBITDA is -1.23. The thresholds are as follows: Strongly Undervalued below -5.03, Undervalued between -5.03 and -3.13, Fairly Valued between 0.68 and -3.13, Overvalued between 0.68 and 2.58, and Strongly Overvalued above 2.58. The current Forward EV/EBITDA of -2.08 falls within the Historic Trend Line -Fairly Valued range.

-2.04

EV/EBIT

Orchestra Biomed Holdings Inc. (OBIO) has a current EV/EBIT of -2.04. The 5-year average EV/EBIT is -2.24. The thresholds are as follows: Strongly Undervalued below -7.79, Undervalued between -7.79 and -5.01, Fairly Valued between 0.54 and -5.01, Overvalued between 0.54 and 3.31, and Strongly Overvalued above 3.31. The current Forward EV/EBIT of -2.04 falls within the Historic Trend Line -Fairly Valued range.

81.60

Orchestra Biomed Holdings Inc. (OBIO) has a current PS of 81.60. The 5-year average PS is 56.10. The thresholds are as follows: Strongly Undervalued below -41.80, Undervalued between -41.80 and 7.15, Fairly Valued between 105.05 and 7.15, Overvalued between 105.05 and 154.01, and Strongly Overvalued above 154.01. The current Forward PS of 81.60 falls within the Historic Trend Line -Fairly Valued range.

-2.92

P/OCF

Orchestra Biomed Holdings Inc. (OBIO) has a current P/OCF of -2.92. The 5-year average P/OCF is -2.84. The thresholds are as follows: Strongly Undervalued below -10.18, Undervalued between -10.18 and -6.51, Fairly Valued between 0.83 and -6.51, Overvalued between 0.83 and 4.51, and Strongly Overvalued above 4.51. The current Forward P/OCF of -2.92 falls within the Historic Trend Line -Fairly Valued range.

-2.92

P/FCF

Orchestra Biomed Holdings Inc. (OBIO) has a current P/FCF of -2.92. The 5-year average P/FCF is -1.15. The thresholds are as follows: Strongly Undervalued below -5.57, Undervalued between -5.57 and -3.36, Fairly Valued between 1.06 and -3.36, Overvalued between 1.06 and 3.27, and Strongly Overvalued above 3.27. The current Forward P/FCF of -2.92 falls within the Historic Trend Line -Fairly Valued range.

Orchestra Biomed Holdings Inc (OBIO) has a current Price-to-Book (P/B) ratio of 5.55. Compared to its 3-year average P/B ratio of 31.04 , the current P/B ratio is approximately -82.12% higher. Relative to its 5-year average P/B ratio of 19.06, the current P/B ratio is about -70.88% higher. Orchestra Biomed Holdings Inc (OBIO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -23.92%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -23.92% , the current FCF yield is about -100.00% lower.

5.55

P/B

Median3y

31.04

Median5y

19.06

-23.87

FCF Yield

Median3y

-23.92

Median5y

-23.92

Competitors Valuation Multiple

The average P/S ratio for OBIO's competitors is , providing a benchmark for relative valuation. Orchestra Biomed Holdings Inc Corp (OBIO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -12.77%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of OBIO increased by 7.50% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.56K to -2.42K.

The secondary factor is the Revenue Growth, contributed -12.77%to the performance.

Overall, the performance of OBIO in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-12.77%

987.00K → 861.00K

Revenue Growth

54.78%

-1.56K → -2.42K

Margin Expansion

-34.51%

-3.65 → -2.39

P/E Change

7.50%

4.00 → 4.30

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Orchestra Biomed Holdings Inc (OBIO) currently overvalued or undervalued?

What is Orchestra Biomed Holdings Inc (OBIO) fair value?

OBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between NaN to NaN according to relative valuation methord.

How does OBIO's valuation metrics compare to the industry average?

What is the current P/B ratio for Orchestra Biomed Holdings Inc (OBIO) as of Dec 16 2025?

As of Dec 16 2025, Orchestra Biomed Holdings Inc (OBIO) has a P/B ratio of 5.55. This indicates that the market values OBIO at 5.55 times its book value.

What is the current FCF Yield for Orchestra Biomed Holdings Inc (OBIO) as of Dec 16 2025?

As of Dec 16 2025, Orchestra Biomed Holdings Inc (OBIO) has a FCF Yield of 0.00%. This means that for every dollar of Orchestra Biomed Holdings Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO) as of Dec 16 2025?

As of Dec 16 2025, Orchestra Biomed Holdings Inc (OBIO) has a Forward P/E ratio of -2.72. This means the market is willing to pay $-2.72 for every dollar of Orchestra Biomed Holdings Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Orchestra Biomed Holdings Inc (OBIO) as of Dec 16 2025?

As of Dec 16 2025, Orchestra Biomed Holdings Inc (OBIO) has a Forward P/S ratio of 0.00. This means the market is valuing OBIO at $0.00 for every dollar of expected revenue over the next 12 months.

OBIO Valuation